Scientific Info and Patent Analysis Grp. 4Q2016 Patent Surveillance – Sunvepra
Patent Analysis Report
To: Pamela Mingo, Paul Scola Date: January 16, 2017
ST00001837
Update for 4Q2016
From: Rohit Agarwal
Intellectual property and R&D solutions
Evalueserve, India
+91 124 463 9923
Therapeutic Area / Project:
Virology / Sunvepra (BMS-650032)
Subject:
Q4, 2016 PATENT SURVEILLANCE UPDATE
Specific Structure Searched:
BMS-650032
Type of Search: Patent Surveillance
Object of Search:
To find patents or patent applications that specifically or generically disclose and/or claim the specified compounds. The search results have been analyzed to present relevant hits and remove duplicates.
Sources Searched:
Structure Search:
REGISTRY Chemical structures and Sequences – 1907 to [present]
DERWENT CHEMISTRY RESOURCE (WPIX) Chemical structures - 1999 to [present].
MARPAT Generic chemical structures from patents – 1961 to [present]
CHEMICAL ABSTRACTS Literature and patents – 1907 to [present]
Keyword Search:
HCAPLUS
WPIX
Summary of Search Strategy:
The structure searched for the study is provided below:
The keywords based search strategy for the study is provided below:
ASUNAPREVIR OR ASV OR 630420-16-5 OR BMS-650032 OR SUNVEPRA
Copies of WO, EP, & US granted patents & patent applications can be downloaded immediately to your desktop by clicking (or use Control-click) on the patent number hyperlinks provided in this report. Occasionally, a patent application number will be incorrectly linked and will not lead to a relevant document. Patent application numbers can usually be recognized by their format.
· Note: You can now directly access the patent documents within the patent search report. By pressing the CTRL key and mouse-clicking the highlighted patent number simultaneously, the pdf document will open up for your review. Please note that there may be a few minutes lag-time when opening the document, depending on network traffic and/or size of the patent. Patents from major patenting authorities (US, EP, WO) are linked in this report. Patents from other select countries (e.g. AU, CA , FR, GB, DE, JP, CH) or from all countries cited in the report can also be linked, if necessary.
· Note: There is a possibility of patent application numbers being hyperlinked within the patent family. These hyperlinks are a result of a “bug” in the software and should be ignored. They will not link to the corresponding application.
If needed, copies of any other patents can usually be obtained from PatBase.
Copies of journal articles may be available by clicking (or use Control-click) on the hyperlinks provided in this report, or from our Electronic Journal collection on Cybrary. They can also be requested using our online photocopy request form
The material in this search report is for in-house use only and is subject to copyright law and policies. In order to comply with copyright law and policies, DO NOT Distribute this report without permission. Contact
Rohit Agarwal if you have any questions.
The BMS Patent Department must be contacted if the patent information provided is to be used for any type of exclusivity or forecast analysis.
Summary of Search Results
A total of five results are identified as interesting for this 4Q2016 update:
· Three results from HCAPLUS;
· Two results from WPIX.
Table of Contents
WO2016169573
WO2016164625
Reference 3. JP2016189746A; Primer pair and probe reagents for PCR-based detection of drug-resistant hepatitis C virus for prognosis assessment, Hiroshima University. 8
WO2016141890
US20160303088
Reference 1. WO2016169573A1; Sesquiterpene lactones as potent and broad spectrum antiviral compounds against all genotypes of Hepatitis C virus (HCV).
Full Text
ACCESSION NUMBER: 2016:1734552 HCAPLUS
DOCUMENT NUMBER: 165:553337
TITLE: Sesquiterpene lactones as potent and broad spectrum
antiviral compounds against all genotypes of Hepatitis
C virus (HCV)
INVENTOR(S): Elsebai, Mahmoud Fahmi
PATENT ASSIGNEE(S): Egypt
SOURCE: PCT Int. Appl., 28pp.
CODEN: PIXXD2
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:
PATENT NO. KIND DATE APPLICATION NO. DATE
------
WO 2016169573 A1 20161027 WO 2016-EG14 20160418
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE,
EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR,
IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA,
PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK,
SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, ZA, ZM, ZW
RW: AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR,
HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS,
SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM,
ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW,
SD, SL, ST, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, RU, TJ, TM
PRIORITY APPLN. INFO.: EG 2015-607 A 20150420
AB The present invention relates to potent HCV entry inhibitors (cynaropicrin
and grosheimol), in addn. to mono-caffoeylquinic acid derivs. which have
also anti-HCV activity but less than cynaropicrin and grosheimol.
IT 630420-16-5, Asunaprevir
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
RN 630420-16-5 HCAPLUS
CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-
(4R)-4-[(7-chloro-4-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-
(cyclopropylsulfonyl)-2-ethenyl-, (1R,2S)- (CA INDEX NAME)
Reference 2. WO2016164625A1; Compositions and methods for the treatment of hepatitis C virus (HCV) infection, Spring Bank Pharmaceuticals.
Full Text
ACCESSION NUMBER: 2016:1650045 HCAPLUS
DOCUMENT NUMBER: 165:497005
TITLE: Compositions and methods for the treatment of
hepatitis C virus (HCV) infection
INVENTOR(S): Iyer, Radhakrishnan P.
PATENT ASSIGNEE(S): Spring Bank Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 169pp.
CODEN: PIXXD2
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:
PATENT NO. KIND DATE APPLICATION NO. DATE
------
WO 2016164625 A1 20161013 WO 2016-US26504 20160407
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE,
EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR,
IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA,
PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK,
SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, ZA, ZM, ZW
RW: AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR,
HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS,
SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM,
ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW,
SD, SL, ST, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, RU, TJ, TM
PRIORITY APPLN. INFO.: US 2015-62144299 P 20150407
US 2015-62169931 P 20150602
US 2015-62215543 P 20150908
US 2015-62215618 P 20150908
AB The present invention features a method of treating a subject infected
with the hepatitis C virus (HCV) infection, the method comprises,
administering to the subject a pharmaceutical compd. selected from e.g.
formula: I (RSp, Rp or Sp isomers)or a prodrug or pharmaceutically
acceptable salt thereof to thereby treat the subject. In some
embodiments, the kit further comprises an addnl. agent (e.g. sofosbuvir)
for treatment. In some embodiments, in a method described herein, the
subject has been further diagnosed with an HIV infection.
IT 630420-16-5, Asunaprevir
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
RN 630420-16-5 HCAPLUS
CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-
(4R)-4-[(7-chloro-4-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-
(cyclopropylsulfonyl)-2-ethenyl-, (1R,2S)- (CA INDEX NAME)
Reference 3. JP2016189746A; Primer pair and probe reagents for PCR-based detection of drug-resistant hepatitis C virus for prognosis assessment, Hiroshima University.
Full Text
ACCESSION NUMBER: 2016:1818385 HCAPLUS
DOCUMENT NUMBER: 165:553812
TITLE: Primer pair and probe reagents for PCR-based detection
of drug-resistant hepatitis C virus for prognosis
assessment
INVENTOR(S): Chayama, Kazuaki; Ochi, Hidenori
PATENT ASSIGNEE(S): Hiroshima University, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 20pp.
CODEN: JKXXAF
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:
PATENT NO. KIND DATE APPLICATION NO. DATE
------
JP 2016189746 A 20161110 JP 2015-72309 20150331
PRIORITY APPLN. INFO.: JP 2015-72309 20150331
AB The primer pair that enable rapid detn. of treatment strategies, probe,
drug-resistant hepatitis C virus detection kit, method for detecting
drug-resistant hepatitis C virus and prognosis method for hepatitis C are
provided. The primer pair, at least 300 consecutive bases contained in
the NS5A region of the genome of hepatitis C virus genotype 1b from the
10th-410th from the 5' end, and it consists of a forward primer and a
reverse primer designed to be contained in the base sequence of the
product of the polymerase chain reaction.
IT 630420-16-5, Asunaprevir
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
RN 630420-16-5 HCAPLUS
CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-
(4R)-4-[(7-chloro-4-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-
(cyclopropylsulfonyl)-2-ethenyl-, (1R,2S)- (CA INDEX NAME)
Reference 4. WO2016141890A1; New fused heterocyclic compounds are hepatitis C virus (HCV) replication inhibitors useful for preventing, managing, treating or lessening the severity of HCV infection or HCV disorder; Sunshine Lake Pharma, Guangdong Dongyangguang Pharm.
Full Text
ACCESSION NUMBER: 2016-57877T [201667] WPIX
TITLE: New fused heterocyclic compounds are hepatitis C virus
(HCV) replication inhibitors useful for preventing,
managing, treating or lessening the severity of HCV
infection or HCV disorder
DERWENT CLASS: A96; B02
INVENTOR: FANG Q; HU B; LIU Z; XIE H; ZHANG J; ZHANG Y
PATENT ASSIGNEE: (SUNS-N) SUNSHINE LAKE PHARMA CO LTD; (GUAN-N) GUANGDONG
DONGYANGGUANG PHARM CO LTD
COUNTRY COUNT: 131
PATENT INFO ABBR.:
PATENT NO KIND DATE WEEK LA PG MAIN IPC
------
WO 2016141890 A1 20160915 (201667)* EN 157[0]
CN 105968101 A 20160928 (201673) ZH
TW 2016032514 A 20160916 (201683) ZH
APPLICATION DETAILS:
PATENT NO KIND APPLICATION DATE
------
WO 2016141890 A1 WO 2016-CN76131 20160311
CN 105968101 A Subst for CN 2015-10108484 20150312
CN 105968101 A Subst for CN 2015-10422786 20150718
CN 105968101 A CN 2016-10141716 20160311
TW 2016032514 A TW 2016-107625 20160311
PRIORITY APPLN. INFO: CN 2015-10422786 20150718
CN 2015-10108484 20150312
CN 2016-10141716 20160311
AN 2016-57877T [201667] WPIX
AB WO 2016141890 A1 UPAB: 20161223
NOVELTY - Fused heterocyclic compounds (I) are new.
DETAILED DESCRIPTION - Fused heterocyclic compounds (I) and their
stereoisomers, geometric isomers, tautomers, enantiomers, N-oxides,
hydrates, solvates, metabolites, salts or prodrugs are new.
A = -(CR7R7a)m-, -CR7=CR7a-, -(CH2)nO-, N=CR7-, -NR7-CR7R7a-,
-CR7R7a-NR7-, -O(CH2)n-, -CR7=N-, -S(CH2)n-, -(CH2)nS- or -NR9a;
X, X1 = N or CR7b;
Y1, Y11 = alkyl, cycloalkyl, heterocyclyl, (hetero)aryl, arylalkyl,
-C(=O)-(CR8R8a)t-N(R9)-R10 or an alpha -amino acid group (all optionally
substituted with 1-4 T1), H or deuterium;
alpha -amino acid group = derived from isoleucine, leucine, lysine,
methionine, phenylalanine, threonine, tryptophane, valine, alanine,
asparagines, aspartic acid, glutamic acid, glutamine, proline, serine,
para-tyrosine, arginine, histidine, cysteine, glycine, sarcosine,
N,N-dimethylglycine, homoserine, norvaline, norleucine, ornithine,
homocysteine, homophenylalanine, phenylglycine, ortho-tyrosine,
meta-tyrosine or hydroxyproline; either
R1-R4 = alkyl, arylalkyl, cycloalkyl, heterocyclyl or (hetero)aryl
(all optionally substituted with 1-4 T1), H or deuterium; or
R1R2+X-CH, R3R4+X1-CH = optionally form 3-8 membered heterocyclyl,
3-8 membered carbocyclyl, fused bicyclyl, fused heterobicyclyl, spiro
bicyclyl or spiroheterobicyclyl (all optionally substituted with 1-4 T1);
R5, R6 = alkyl, haloalkyl, alkenyl, alkynyl, heterocyclyl,
cycloalkyl, (hetero)aryl, arylalkyl, alkoxyalkyl, alkoxy,
(hetero)arylamino, (hetero)arylalkylamino, heteroaryloxy, heteroarylalkyl,
(hetero)arylalkoxy, heterocyclyloxy, heterocyclylalkoxy,
heterocyclylamino, alkylacyl, alkylacyloxy, alkoxyacyl,
heterocyclylalkylamino or aryloxy (all optionally substituted with 1-4
T1), H, deuterium, oxo (=O), OH, amino, halo, CN, mercapto or NO2;
R7, R7a, R7b, R8, R8a, R9a = deuterated alkyl, alkyl, haloalkyl,
alkoxy, alkenyl, alkynyl, heterocyclyl, cycloalkyl, (hetero)aryl,
arylalkyl, alkoxyalkyl, heteroarylalkyl, cycloalkylalkyl,
heterocyclylalkyl, (hetero)arylamino, (hetero)arylalkylamino,
heteroaryloxy, arylalkoxy, heteroarylalkoxy, heterocyclyloxy,
heterocyclylalkoxy, heterocyclylamino, alkyl-OC(=O)-, alkyl-C(=O)-,
carbamoyl, alkyl-OS(=O)r-, alkyl-S(=O)rO-, alkyl-OS(=O)rO-, alkyl-S(=O)r-,
heterocyclylalkylamino or aryloxy (all optionally substituted with 1-4
T1), H, deuterium, oxo (=O), OH, amino, halo, CN, mercapto or NO2;
R9, R10 = alkyl, cycloalkyl, heterocyclyl, (hetero)aryl, arylalkyl,
alkyl-OC(=O)-, alkyl-C(=O)-, carbamoyl, alkyl-OS(=O)r-, alkyl-S(O)rO-,
alkyl-S(=O)r- or aminosulfonyl (all optionally substituted with 1-4 T1), H
or deuterium;
m = 1-4;
r = 0-2; and
T1 = OH, deuterium, amino, halo, CN, (hetero)aryl, alkoxy
(optionally substituted), alkylamino, alkylthio, alkyl, haloalkyl,
alkoxyalkyl, haloalkoxyalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl,
mercapto, NO2, aryloxy, arylamino, heteroaryloxy, heteroarylalkyl, oxo
(=O), carboxy, OH, OH substituted alkyl-C(=O)-, alkyl-C(=O)-,
alkyl-S(=O)-, alkyl-S(=O)2, OH substituted alkyl-S(=O)-, OH substituted
alkyl-S(=O)2 or carboxy substituted alkoxy.
An INDEPENDENT CLAIM is also included for a composition comprising
(I) and a carrier, excipient, diluents, adjuvant and/or vehicle.
ACTIVITY - Antiinflammatory; Hepatotropic; Virucide.
MECHANISM OF ACTION - HCV replication inhibitor; HCV viral protein
function inhibitor. The effect of (I) to inhibit HCV replication was
tested in HCV GT1b L31V resistant strain using biological assays. The
result showed that ((S)-1-((S)-2-(5-(7-(2-((S)-1-((S)-2-
methoxycarbonylamino-3-methyl-butyryl)-pyrrolidin-2-yl)-4,5-dihydro-1H-
naphtho(1,2-d)imidazol-7-yl)-indan-4-yl)-1H-imidazol-2-yl)-pyrrolidine-1-
carbonyl)-2-methyl-propyl)-carbamic acid methyl ester exhibited EC50 value
of 0.002 nM.
USE - (I) are useful for preventing, managing, treating or
lessening the severity of HCV infection or HCV disorder in a subject (all
claimed).
ADVANTAGE - (I): have good inhibitor effect on HCV GT1a, GT1b,
GT2a, GT3a, GT4b, GT5a, GT6a or HCVGT1b L31V, GT1b Y93H resistant strains;
and have anti drug resistance effect and good bioavailability.
AN.S DCR-2088724
CN.P ASUNAPREVIR
CN.S {(S)-1-[(2S,4R)-4-(7-Chloro-4-methoxy-isoquinolin-1-yloxy)-2-((1R,2S)-1-
cyclopropanesulfonylaminocarbonyl-2-vinyl-cyclopropylcarbamoyl)-
pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl}-carbamic acid tert-butyl
ester
SDCN RB3B4M
Reference 5. US20160303088A1; Improving pharmacokinetics of drug used to treat HIV, comprises administering substituted (benzyl-phenyl-(thiazolylmethoxycarbonylamino)-pentyl)- carbamic acid thiazolylmethyl ester; Gilead Sci.
Full Text
ACCESSION NUMBER: 2016-64945N [201676] WPIX
CROSS REFERENCE: 2008-M29459; 2009-L57970; 2011-F02293; 2011-L18966;
2011-P67662; 2012-M13647; 2013-H43011; 2014-B53942;
2014-G76106; 2015-036272; 2015-306730; 2015-464330;
2016-15478R; 2016-15508T
TITLE: Improving pharmacokinetics of drug used to treat HIV,
comprises administering substituted
(benzyl-phenyl-(thiazolylmethoxycarbonylamino)-pentyl)-